We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

First-in-class Drug Holds Promise for Therapy-resistant Breast Cancer

News   Aug 09, 2017 | Original story from UT Southwestern

 
First-in-class Drug Holds Promise for Therapy-resistant Breast Cancer

Structure of estrogen receptor beta. Credit: Doxepine

 
 
Advertisement
 

RELATED ARTICLES

Uncovering a Novel Mechanism for Disposing of Misfolded Proteins

News

About 30 years ago, Dr. Richard Sifers set out on a journey to discover why people with a rare condition known as alpha1-antitrypsin (AAT) deficiency present with high variation in the severity of liver disease. His journey led him to the discovery of fundamental underpinnings of this condition and, unexpectedly, to uncovering a novel cellular mechanism for disposing of misfolded proteins.

READ MORE

Neuropilin-1 Identified as a Facilitator for SARS-CoV-2 Entry Into Cells’ Interior

News

The coronavirus SARS-CoV-2 is known to infect cells via the receptor ACE2. An international research team under German-Finnish coordination has now identified neuropilin-1 as a factor that can facilitate SARS-CoV-2 entry into the cells’ interior.

READ MORE

CRISPR Therapy Restores Retinal and Visual Function in Mice

News

A breakthrough study, led by researchers from the University of California, Irvine, results in the restoration of retinal and visual functions of mice models suffering from inherited retinal disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE